CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $3.49M, lower than 95% of all stocks globally
- PositionReturn on equity is -378%, lower than 95% of its Biotechnology peers (median -24.5%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.66BUSDvs all stocks (USD)
Revenue (TTM)
3.49MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.57xvs all stocks
52-Week Change
104.53%vs all stocks
Market Capitalization
2.66BUSDvs all stocks (USD)
Enterprise Value
1.75BUSDvs all stocks (USD)
Forward P/E
-11.89xvs Biotechnology peers
Price to Book (MRQ)
9.87xvs Biotechnology peers
Enterprise to Revenue
501.10xvs Biotechnology peers
Enterprise to EBITDA
-14.34xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-3239.10%vs Biotechnology peers
Return on Assets (TTM)
-33.34%vs Biotechnology peers
Return on Equity (TTM)
-378.00%vs Biotechnology peers
Revenue (TTM)
3.49MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0130USDUpdated Jul 18, 2026Quarterly Revenue Growth
-38.70%vs Biotechnology peers
Gross Profit (TTM)
-54.61MUSDvs all stocks (USD)
EBITDA (TTM)
-121.90MUSDvs all stocks (USD)
Net Income (TTM)
-663.40MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-105.92MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-55.53MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
127.00KUSDFY2025 · Dec 31, 2025Revenue
4.09MUSDFY2025 · Dec 31, 2025Operating Income
-113.35MUSDvs all stocks (USD)
Pre-tax Income
-659.85MUSDFY2025 · Dec 31, 2025Income Tax Expense
298.00KUSDFY2025 · Dec 31, 2025Net Income
-660.15MUSDFY2025 · Dec 31, 2025EBIT
-658.69MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-113.45MUSDFY2025 · Dec 31, 2025Research & Development
53.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
65.09MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.48MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.16MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.91USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.91USDFY2025 · Dec 31, 2025Basic Shares Outstanding
226.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
226.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-660.15MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
100.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
-619.04MUSDFY2025 · Dec 31, 2025Free Cash Flow
-619.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
85.30MUSDFY2025 · Dec 31, 2025Income Tax Paid
589.00KUSDFY2025 · Dec 31, 2025Interest Paid
793.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-660.15MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.01MUSDFY2025 · Dec 31, 2025Stock-based Compensation
14.21MUSDFY2025 · Dec 31, 2025Other Non-cash Items
26.81MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.70MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
766.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-901.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-9.97MUSDFY2025 · Dec 31, 2025Net Acquisitions
4.64MUSDFY2025 · Dec 31, 2025Purchase of Investments
-101.94MUSDFY2025 · Dec 31, 2025Sale of Investments
9.05MUSDFY2025 · Dec 31, 2025Other Investing Activity
-10.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-99.16MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
-6.63MUSDFY2025 · Dec 31, 2025Other Financing Charges
-13.95MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
237.54MUSDFY2025 · Dec 31, 2025Shares Outstanding
365.56MSharesUpdated Jul 18, 2026Float Shares
303.81MSharesUpdated Jul 18, 2026Shares Short
30.26MSharesUpdated Jul 18, 2026Short Ratio
3.38daysvs all stocks
Short % of Shares Outstanding
9.71%vs all stocks
% Held by Insiders
2.35%vs all stocks
% Held by Institutions
43.89%vs all stocks
Total Cash (MRQ)
230.77MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6270USDUpdated Jul 18, 2026Total Debt (MRQ)
5.14MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0259xvs Biotechnology peers
Current Ratio (MRQ)
10.02xvs Biotechnology peers
Book Value per Share (MRQ)
0.5430USDUpdated Jul 18, 2026Total Assets
292.72MUSDvs all stocks (USD)
Total Current Assets
275.68MUSDFY2025 · Dec 31, 2025Total Liabilities
70.72MUSDFY2025 · Dec 31, 2025Total Non-current Assets
17.04MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
47.24MUSDFY2025 · Dec 31, 2025Total Current Liabilities
23.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
85.30MUSDFY2025 · Dec 31, 2025Other Short-term Investments
170.74MUSDFY2025 · Dec 31, 2025Accounts Receivable
667.00KUSDFY2025 · Dec 31, 2025Accounts Payable
4.91MUSDFY2025 · Dec 31, 2025Short-term Debt
271.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
1.52MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.14MUSDFY2025 · Dec 31, 2025Long-term Debt
1.80MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.06MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.63MUSDFY2025 · Dec 31, 2025Retained Earnings
-1.36BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
222.00MUSDvs all stocks (USD)
52-Week Low
3.06USDUpdated Jul 18, 202652-Week High
7.22USDUpdated Jul 18, 202652-Week Change
104.53%vs all stocks
Beta
1.57xvs all stocks
50-Day MA
4.44USDUpdated Jul 18, 2026200-Day MA
4.30USDUpdated Jul 18, 2026Avg 10-Day Volume
9.04MSharesUpdated Jul 18, 2026Avg 30-Day Volume
9.04MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.84USDUpdated Jul 18, 2026Other Income / Expense
-546.82MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -378%, lower than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: -3.78Industry median: -0.25Industry P5: -1.55Peers compared: 197
Financial Health
Altman Z-Score 9.67: safe zoneNotable
Altman Z-Score: 9.67
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $3.49M, lower than 95% of all stocks globallySignificant
Revenue (USD): 3,488,000Global P5: 30,274,777.221
Market cap is $2.66B, above the global median of $1.15BNotable
Market cap (USD): 2,658,163,386Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Sinocelltech Group Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Maravai Lifesciences Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
MicroPort Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Travere Therapeutics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Iovance Biotherapeutics, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Precigen Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC